Maximus Details Strong FY25 Performance, High Executive Payouts, and Strategic Growth Initiatives
MMS sits 55% above its 52-week low of $63.77.
Summary
Maximus's definitive proxy statement details exceptional fiscal year 2025 financial performance, including significant revenue growth and a 20% increase in adjusted EPS, leading to executive compensation payouts well above target levels.
Key Events · Corporate Governance and Compliance · MMS
-
Exceptional FY2025 Financial Performance
Maximus reported full-year revenue of $5.43 billion, 3.9% organic revenue growth, a 12.9% adjusted EBITDA margin, and adjusted diluted EPS of $7.36, representing a 20% increase from the prior fiscal year.
-
High Executive Compensation Achievement
The Executive Bonus Plan (EBP) payouts were capped at 220% of target, and Performance Stock Unit (PSU) tranches for fiscal years 2023-2025, 2024-2026, and 2025-2027 vested at 200% of target, reflecting strong operational execution against internal goals.
-
Strategic Growth and AI Integration
The company emphasized progress across its strategic growth pillars: tech-enabled customer service, the future of health, and technology modernization, with a continued focus on integrating AI and automation technologies.
-
Notable Contract Wins
Maximus secured significant contracts in FY2025, including a $123 million contract with the National Energy Technology Laboratory and two contracts with the U.S. Air Force totaling $163 million, expanding its defense technology portfolio.
Analysis · MMS · Trade & Services
This definitive proxy statement provides a comprehensive review of Maximus's strong fiscal year 2025 performance, which significantly exceeded internal targets and led to substantial executive compensation payouts. The company reported full-year revenue of $5.43 billion, 3.9% organic revenue growth, a 12.9% adjusted EBITDA margin, and a 20% increase in adjusted diluted EPS to $7.36. These results underscore robust demand for its services and effective operational execution. The filing also highlights the company's strategic focus on tech-enabled customer service, the future of health, and technology modernization, with a particular emphasis on expanding AI capabilities. While the top-line financial results were previously disclosed in the 10-K, this filing provides granular detail on the achievement of performance metrics and the resulting executive incentives, reinforcing a positive outlook for the company's operational strength and strategic direction.
At the time of this filing, MMS was trading at $98.93 on NYSE in the Trade & Services sector, with a market capitalization of approximately $5.4B. The 52-week trading range was $63.77 to $99.28. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.